143 related articles for article (PubMed ID: 35833685)
1. High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV - but HIV viremia matters?
Gianserra L; Donà MG; Giuliani E; Stingone C; Pontone M; Buonomini AR; Giuliani M; Pimpinelli F; Morrone A; Latini A
AIDS; 2022 Jul; 36(9):1319-1320. PubMed ID: 35833685
[No Abstract] [Full Text] [Related]
2. High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV - but HIV viremia matters?
Xu X; Vesterbacka J; Aleman S; Nowak P;
AIDS; 2022 Mar; 36(3):479-481. PubMed ID: 35084386
[TBL] [Abstract][Full Text] [Related]
3. Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies.
Kohmer N; Rabenau HF; Ciesek S; Krämer BK; Göttmann U; Keller C; Rose D; Blume C; Thomas M; Lammert A; Lammert A
Nephrol Dial Transplant; 2022 May; 37(6):1132-1139. PubMed ID: 35099023
[TBL] [Abstract][Full Text] [Related]
4. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial.
Bonelli M; Mrak D; Tobudic S; Sieghart D; Koblischke M; Mandl P; Kornek B; Simader E; Radner H; Perkmann T; Haslacher H; Mayer M; Hofer P; Redlich K; Husar-Memmer E; Fritsch-Stork R; Thalhammer R; Stiasny K; Winkler S; Smolen JS; Aberle JH; Zeitlinger M; Heinz LX; Aletaha D
Ann Rheum Dis; 2022 May; 81(5):687-694. PubMed ID: 35027397
[TBL] [Abstract][Full Text] [Related]
5. Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy.
Jedicke N; Stankov MV; Cossmann A; Dopfer-Jablonka A; Knuth C; Ahrenstorf G; Ramos GM; Behrens GMN
HIV Med; 2022 May; 23(5):558-563. PubMed ID: 34725907
[TBL] [Abstract][Full Text] [Related]
6. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
7. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
[TBL] [Abstract][Full Text] [Related]
8. Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months.
Ponticelli D; Antonazzo IC; Caci G; Vitale A; Della Ragione G; Romano ML; Borrelli M; Schiavone B; Polosa R; Ferrara P
J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34697627
[No Abstract] [Full Text] [Related]
9. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
10. Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis.
Verleye A; Wijtvliet V; Abrams S; Hellemans R; Bougrea R; Massart A; Pipeleers L; Wissing KM; Ariën KK; De Winter BY; Van Damme P; Abramowicz D; Ledeganck KJ
Nephrol Dial Transplant; 2022 Jul; 37(8):1566-1575. PubMed ID: 35544087
[TBL] [Abstract][Full Text] [Related]
11. Safety Profile and Low Risk of Disease Relapse After BNT162b2 mRNA SARS-CoV-2 Vaccination in Patients With Rare Rheumatic Diseases.
Fornaro M; Venerito V; Iannone F; Cacciapaglia F
J Rheumatol; 2022 Mar; 49(3):334-335. PubMed ID: 35033998
[No Abstract] [Full Text] [Related]
12. Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab.
Altieri M; Capuano R; Conte M; Donnarumma G; Grimaldi E; Coppola N; Galdiero M; d'Ambrosio A; Tedeschi G; Gallo A
Neurol Sci; 2022 May; 43(5):2947-2949. PubMed ID: 35171373
[TBL] [Abstract][Full Text] [Related]
13. Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV.
Chammartin F; Kusejko K; Pasin C; Trkola A; Briel M; Amico P; Stoekle MP; Eichenberger AL; Hasse B; Braun DL; Schuurmans MM; Müller TF; Tamm M; Mueller NJ; Rauch A; Koller MT; Günthard HF; Bucher HC; Speich B; Abela IA;
AIDS; 2022 Aug; 36(10):1465-1468. PubMed ID: 35876706
[TBL] [Abstract][Full Text] [Related]
14. Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities.
Trigueros M; Pradenas E; Palacín D; Muñoz-López F; Ávila-Nieto C; Trinité B; Bonet-Simó JM; Isnard M; Moreno N; Marfil S; Rovirosa C; Puig T; Grau E; Chamorro A; Martinez A; Toledo R; Font M; Ara J; Carrillo J; Mateu L; Blanco J; Clotet B; Prat N; Massanella M;
Age Ageing; 2022 May; 51(5):. PubMed ID: 35595256
[TBL] [Abstract][Full Text] [Related]
15. Seroconversion after anti-SARS-CoV-2 mRNA vaccinations among moderate-to-severe psoriatic patients receiving systemic biologicals-Prospective observational cohort study.
Piros ÉA; Cseprekál O; Görög A; Hidvégi B; Medvecz M; Szabó Z; Olajos F; Barabás E; Galajda N; Miheller P; Holló P
Dermatol Ther; 2022 May; 35(5):e15408. PubMed ID: 35218276
[TBL] [Abstract][Full Text] [Related]
16. BNT162b2 mRNA SARS-CoV-2 vaccination does not cause upregulation of endothelial activation markers or hypercoagulability: A prospective, single-arm, longitudinal study.
Lim XR; Leung BP; Sum CLL; Lim GH; Chua CG; Tu TM; Ramanathan K; Huang MY; Howe HS; Fan BE
Am J Hematol; 2022 Apr; 97(4):E141-E144. PubMed ID: 35015303
[No Abstract] [Full Text] [Related]
17. Characterization of Serum and Mucosal SARS-CoV-2-Antibodies in HIV-1-Infected Subjects after BNT162b2 mRNA Vaccination or SARS-CoV-2 Infection.
Schmidt KG; Harrer EG; Tascilar K; Kübel S; El Kenz B; Hartmann F; Simon D; Schett G; Nganou-Makamdop K; Harrer T
Viruses; 2022 Mar; 14(3):. PubMed ID: 35337058
[TBL] [Abstract][Full Text] [Related]
18. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
Front Immunol; 2021; 12():704773. PubMed ID: 34220867
[TBL] [Abstract][Full Text] [Related]
19. Multisystem inflammatory syndrome in children after BNT162b2 messenger RNA SARS-CoV-2 vaccination.
Sakaida K; Iwashima S; Katsuki J; Sato K; Miyairi I
Pediatr Int; 2023 Jan; 65(1):e15441. PubMed ID: 36513963
[No Abstract] [Full Text] [Related]
20. Immediate reactions after mRNA SARS-CoV-2 vaccination.
Jeimy S; Wong T; Song C
CMAJ; 2021 Dec; 193(48):E1842. PubMed ID: 34772737
[No Abstract] [Full Text] [Related]
[Next] [New Search]
